Jeffrey R. Stewart - Mar 13, 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, CHIEF COMMERCIAL OFFICER
Signature
Steven L. Scrogham, attorney-in-fact for Jeffrey R. Stewart
Stock symbol
ABBV
Transactions as of
Mar 13, 2023
Transactions value $
-$8,089,998
Form type
4
Date filed
3/15/2023, 05:00 PM
Previous filing
Mar 2, 2023
Next filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $1.2M +21.8K +23.64% $54.86 114K Mar 13, 2023 Direct
transaction ABBV Common Stock, $0.01 par value Sale -$3.32M -21.8K -19.12% $152.30 92.3K Mar 13, 2023 Direct F1
transaction ABBV Common Stock, $0.01 par value Sale -$4.77M -31.3K -33.94% $152.27 60.9K Mar 13, 2023 Direct F2
holding ABBV Common Stock, $0.01 par value 1.34K Mar 13, 2023 By spouse in trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Options Exercise -$1.2M -21.8K -100% $54.86 0 Mar 13, 2023 Common Stock 21.8K $54.86 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.73 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reporting person disclaims beneficial ownership of all securities held by his spouse.
F4 Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section16 under Rule 16b-3.